Research ArticlePharmaceutics, Drug Delivery and Pharmaceutical TechnologyInjectable PLGA/Hydroxyapatite/Chitosan Microcapsules Produced by Supercritical Emulsion Extraction Technology: An In Vitro Study on Teriparatide/Gentamicin Controlled Release
Introduction
Osteoporosis affects more than 75 million people in USA, Europe, and Japan,1 with a consequent increase in bone fragility and susceptibility to fracture at any skeletal site,2, 3 and an enormous economic burden on health care systems in Europe and worldwide. Teriparatide (THA) is currently Food and Drug Administration–approved for the treatment of osteoporosis and osteoarthritis4 and may strongly improve fracture healing or repair bone defects.5 THA has been reported to accelerate and improve healing at the standard available dose of 20-40 mg/day, especially for aged patients with a fracture.6, 7, 8 THA is the recombinant 1-34 amino acid segment of the parathyroid hormone (PHT) with a molecular weight of 4117.72 g/mol. THA binds to the receptor for PHT present in bone and stimulates the G-protein-related production of cyclic adenosine monophosphate.9 During treatment, an increase in trabecular connectivity and cortical thickness is observed, with consequent improvement of the microarchitectural strength of bone10; THA may also stimulate mesenchymal stem cell proliferation and stem cell maturation in the musculoskeletal lineage.11
Despite the demonstrated clinical efficacy of THA, patient acceptance and compliance is limited by the need for daily subcutaneous injections. The development of an equally efficient formulation not requiring daily injections would significantly expand the present market.12, 13 Moreover, among all the possible drug administration, a local therapy, if indicated, has many potential advantages such as circumventing possible adverse side effects resulting from systemic administration, decreasing dose or number of dosages, and maintaining local agent levels within a desirable range.14 Several devices have been already explored for THA (and PHT)-controlled delivery such as, multipulse subcutaneous implantable devices15, 16 or microchip,17 coated microneedle patch system,18 or implantable biopolymer scaffold.19 Eli Lilly recently has launched a new THA formulation in the injectable form and Daiichi and West Pharmaceuticals are working on nasal formulations.
Poly-lactic-co-glycolic acid (PLGA) excellent biocompatibility and biodegradability makes this biopolymer an appropriate carrier for drug delivery; in addition, PLGA has been approved by the Food and Drug Administration as a safe biomaterial for clinical applications. The intraarticular and local injection of microcarriers, fabricated with PLGA and able of controlled and local THA delivery may be an interesting option.20 Recently, it was reported a successful suppression of osteoarthritis progression in rats replacing the single-dose injection, required every 3 days, by using PLGA (65:35) microspheres able to release the drug for 19 days with a concentration range of 5-100 nM (covering 10 nM) at 37°C. The in vivo study showed after intraarticular treatment with either 3 days/injection or PLGA microspheres (15 days/injection) for 5 weeks a similar effect on suppressing papain-induced osteoarthritis changes, by decreasing production of GAG and Col II and increasing Col III in rat knee cartilage.21
An engineered size distribution, as well as, excellent drug encapsulation efficiency are very important fabrication parameters for microcapsules industrial production to ensure a controlled and reproducible drug sustained release formulation. In this sense, supercritical fluid technologies may offer an improved control over the morphology and composition of microdevices and nanodevices coupled with good fabrication process robustness.22, 23, 24, 25 The basic idea of use supercritical carbon dioxide (SC-CO2) as the extracting agent of the oily phase of an emulsion, leading solvent-free microspheres was proposed in 200626; the original process was performed using a batch operative layout, then was later improved by other authors and named supercritical emulsion extraction (SEE).27, 28, 29 After these pioneering articles, new SEE continuous process layout was proposed using a countercurrent-packed tower to reduce the emulsion processing time (few minutes of residence time), improve the encapsulation efficiency (especially if double emulsions are treated), and assured higher process reproducibility.30
In this work, we will explore the SEE technology (continuous layout) to fabricate an engineered, versatile, and multiloaded PLGA microdevice for THA sustained release. Particularly, hydroxyapatite (HA) will be embedded into the microcarrier structure because it is widely used in bone tissue engineering and is reported to be good matrix for bone cell differentiation and mineralization.31 Indeed, in vitro and in vivo studies of biopolymer/HA composites found that osteoblast cells adhered to HA preferentially, leading to subsequent cell proliferation, and the composite implants displayed good bone integration and osteoconductivity in rabbit models.32, 33 Artificial defects induced in the osteoporotic bone of the rat mandible were also successfully reconstructed following implantation of HA nanoparticles coated with cholecalciferol-loaded PLGA devices,34 whereas hollow HA microspheres loaded with clinically safe doses of bone morphogenetic protein–2 could provide promising implants for healing nonloaded bone defects.35 Chitosan (Chi) will be also chosen because it was already used to repair critical bone defects36, 37, 38; some authors also indicated that Chi/PLGA microsphere combined with appropriate drug delivery can achieve accelerated bone healing both in vitro and in vivo and were able to guide bone formation in a rabbit ulnar critical-sized-defect model.39 In our hypothesis, the basic inorganic component of HA could interfere with the acidic degradation products of PLGA polymer, affecting the drug release, whereas the chitosan coating would additionally delay the drug release. Gentamicin (Gen) is largely used in the treatment of osteomyelitis,40 and it will be also coencapsulated in the microcarriers to understand SEE versatility in producing microcapsules with a simultaneous release of different molecules.
Different oil-in-water (o-w) and water-in-oil-in-water (w-o-w) emulsions will be processed by SEE and the fabricated microcapsule (1) morphology will be observed using scanning electron microscopy, (2) particle size distribution (PSD) and zeta potential measured by a laser scattering. HA loading and its dispersion in the biopolymer matter will be measured by thermogravimetric analysis (TGA) and energy-dispersive X-ray analysis (EDX), respectively, whereas drugs loading and encapsulation efficiency will be monitored by chemical analysis. The effect of HA embedding and chitosan coating on drugs release will be both explored by monitor the in vitro drug release profiles obtained in PBS medium at 37°C. THA and Gen apparent diffusivities will be calculated by fitting the release profiles obtained from the different microcapsules.
Section snippets
Materials
CO2 (99.9%) was purchased from SON (Naples, Italy). Polyvinyl alcohol (mol wt: 30,000-55,000), polysorbate (Tween80), teriparatide (THA, lyophilized powder, purity 99.9%; water solubility 0.40 mg/mL), gentamicin sulfate (Gen, powder, purity 99.9%; water solubility 50 mg/mL) were received from Sigma Aldrich Co. (Milan, Italy). Hydroxyapatite nanoparticles (HA, nanopowder, mean size ≤100) were supplied by Sigma-Aldrich (PLGA 50:50, RESOMER® RG 504H, Mol wt: 38,000-54,000) was obtained from Evonik
SEE Processing of Emulsions
In the SEE process, the scope of the packed column is to provide a very large surface for contact between the falling liquid phase and the going up gas phase (liquid emulsion and supercritical extracting agent, respectively); as a consequence, SC-CO2 rapidly diffuses into the oily phase of emulsion, causing the formation of an “expanded” oily phase droplet in where the solvent is rapidly extracted. A fast polymer hardening is obtained with the formation of solid microspheres (see SEE process
Conclusions and Perspectives
SEE confirmed to be a green, flexible, and robust technology to fabricate multiloaded microcapsules, coupling the efficiency of continuous operation to easy process scalability. Both Gen and THA molecules were not chemically modified or degraded by the encapsulation technology and should maintain their biological activity. The emulsion formulations explored, coupled with the supercritical technology, can be used to fabricate versatile microdevices, able to control the drug release over a wide
References (58)
- et al.
Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing
Bone
(2005) - et al.
Pulsatile release of parathyroid hormone from an implantable delivery system
Biomaterials
(2007) - et al.
The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres
Biomaterials
(2004) - et al.
Sustained release of PTH(1-34) from PLGA microspheres suppresses osteoarthritis progression in rats
Acta Biomater
(2012) - et al.
Chitosan scaffolds formation by a supercritical freeze extraction process
J Supercrit Fluids
(2014) - et al.
Polymethylmethacrylate (PMMA) sub-microparticles produced by supercritical assisted injection in a liquid antisolvent
J Supercrit Fluids
(2014) - et al.
Supercritical fluids applications in nanomedicine
J Supercrit Fluids
(2015) - et al.
Production of PLGA micro-and nanocomposites by supercritical fluid extraction of emulsions: I. Encapsulation of lysozyme
J Supercrit Fluid
(2009) - et al.
NSAID drugs release from injectable microspheres produced by supercritical fluid emulsion extraction
J Pharm Sci
(2010) - et al.
Injectable PLGA/hydrocortisone formulation produced by continuous supercritical emulsion extraction
Int J Pharm
(2013)
Developing bioactive composite materials for tissue replacement
Biomaterials
Enhanced osteoblast adhesion on hydrothermally treated hydroxyapatite/titania/poly(lactide-co-glycolide) sol–gel titanium coatings
Biomaterials
Multifunctional hydroxyapatite and poly(D,L-lactide-co-glycolide) nanoparticles for the local delivery of cholecalciferol
Mater Sci Eng C
Preparation of resorbable carbonate-substituted hollow hydroxyapatite microspheres and their evaluation in osseous defects in vivo
Mater Sci Eng C
Structural and human cellular assessment of a novel microsphere-based tissue engineered scaffold for bone repair
Biomaterials
Polysaccharide colloidal particles as delivery systems for macromolecules
Adv Drug Deliv Rev
Chitosan and its derivatives for tissue engineering applications
Biotechnol Adv
Chitosan-poly(lactide-co-glycolide) microsphere-based scaffolds for bone tissue engineering: in vitro degradation and in vivo bone regeneration studies
Acta Biomater
Improvement of gentamicin poly(d,l-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures
Biomaterials
Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections
Int J Pharm
Development and validation of RP-HPLC and RP-UPLC methods for quantification of parathyroid hormones (1-34) in medicinal product formulated with meta-cresol
J Pharm Anal
Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles
Biomaterials
Mathematical modeling of bioerodible, polymeric drug delivery systems
Adv Drug Deliv Rev
Bioerodible implants with programmable drug release1
J Control Release
In vitro evaluation of the hydrolytic degradation of dispersed and aggregated poly(dl-lactide-co-glycolide) microspheres
J Control Release
Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres—a review
J Control Release
PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release
Eur J Pharm Sci
Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite
J Control Release
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-A review
Int J Pharm
Cited by (33)
3D printed PLGA scaffold with nano-hydroxyapatite carrying linezolid for treatment of infected bone defects
2024, Biomedicine and PharmacotherapyProduction of biopharmaceutical dried-powders using supercritical CO<inf>2</inf> technology
2022, Journal of Supercritical FluidsFabrication and applications of bioactive chitosan-based organic-inorganic hybrid materials: A review
2021, Carbohydrate PolymersCitation Excerpt :Porta et al. prepared injectable PLGA/HAP/CS microcapsules with high encapsulation efficiency and reduced “burst release of the drug” (almost 3% release/day) through supercritical emulsion extraction technology to achieve effective controlled release of teriparatide and gentamicin. The authors attribute this outstanding controlled release effect to the antagonism between the alkaline inorganic components (HAP) and the acid degradation products of PLGA and the high encapsulation efficiency of the CS coating (Della Porta et al., 2016). HAP/CS/ fullerene (C60) beads were fabricated by Sukhodub et al. as the drug carriers of anaesthesumum (a hydrophobic anesthetic).
Particle engineering principles and technologies for pharmaceutical biologics
2021, Advanced Drug Delivery ReviewsCitation Excerpt :The supercritical emulsion extraction (SEE) technique employing SC-CO2 as an extracting agent of the oily phase of an emulsion has recently been proposed for the production of the microparticles loading pharmaceutical biologics [252]. In brief, the emulsion droplets or double emulsion droplets are fabricated by SEDE and DESE procedure, then the organic solvent is extracted by SC-CO2, leading to the precipitation of particles [252,310,317–320]. Therefore, in addition to the CMAs and CPPs that influence the final particle characteristics involved in the traditional SESE and DESE technology, the operation pressure and temperature affecting the state of SC-CO2 as well as the liquid to gas ratios can also be considered as CPPs [252,319].
Formulation and in vitro characterization of long-acting PLGA injectable microspheres encapsulating a peptide analog of LHRH
2021, Journal of Materials Science and TechnologySupercritical emulsion extraction fabricated PLA/PLGA micro/nano carriers for growth factor delivery: Release profiles and cytotoxicity
2021, International Journal of Pharmaceutics
This article contains supplementary material available from the authors by request or via the Internet at http://dx.doi.org/10.1016/j.xphs.2016.05.002.